AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune diseases, today announced the publication of new ...
Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ ...
80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg ...
A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...
EMERYVILLE, Calif., Aug. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, ...
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated ...
Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow UpLifileucel Launch in Previously Treated Advanced ...
WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...
Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of two abstracts for poster presentations at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback